952006-34-7

Basic information

• Product Name: 3-(2-chloro-2-oxoacetyl)-1H-indol-4-yl acetate
• Synonyms: 3-(2-chloro-2-oxoacetyl)-1H-indol-4-yl acetate
• CAS NO: 952006-34-7
• Molecular Formula: C₁₂H₈ClNO₄
• Molecular Weight: 266
• EINECS: -0
• Mol File: 952006-34-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 478.7±48.0 °C(Predicted)
• Appearance: /
• Density: 1.479±0.06 g/cm3(Predicted)
• PKA: 13.67±0.30(Predicted)
• CAS DataBase Reference: 3-(2-chloro-2-oxoacetyl)-1H-indol-4-yl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-chloro-2-oxoacetyl)-1H-indol-4-yl acetate(952006-34-7)
• EPA Substance Registry System: 3-(2-chloro-2-oxoacetyl)-1H-indol-4-yl acetate(952006-34-7)

Safety Data

• Hazardous Substances Data: 952006-34-7(Hazardous Substances Data)

Upstream product

• 79-37-8 oxalyl dichloride 
• 5585-96-6 acetic acid 1H-indol-4-yl ester 
• 2380-94-1 1H-indol-4-ol 

Downstream Products

• 520-53-6 psilocin 
• 1154742-29-6 C₂₃H₂₁N₃O₅ 
• 92292-84-7 2-Acetoxy-N,N-dimethyltryptamine 
• 520-52-5 psilocybin 
• 791537-89-8 3-(2-(dibenzylamino)ethyl)-1H-indol-4-ol 
• 21420-58-6 [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate 
• 77872-23-2 3-(2-(dibenzylamino)-2-oxoacetyl)-1H-indol-4-yl acetate 

Relevant articles and documents

AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS

The present disclosure includes azetidinyl tryptamines and methods of treating psychiatric disorders with such compounds. Also provided are pharmaceutical compositions that include azetidinyl tryptamines.

An Improved, Practical, and Scalable Five-Step Synthesis of Psilocybin

Described herein is an improved synthesis of 3-[2-(dimethylamino)ethyl]-1 H -indol-4-yl dihydrogen phosphate (psilocybin). The protocol outlines: synthesis of multigram quantities of psilocybin, identification of critical in-process parameters, and isolation of psilocybin without the use of chromatography, TLC, or aqueous workup. The synthesis furnishes psilocybin in five steps in 23percent overall yield from an inexpensive acetoxyindole starting material. With specific focus on process control and impurity fate and removal, the improved procedure is amenable to providing high-quality psilocybin.

Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns

The effects of introducing simple halogen, alkyl, and alkoxy substituents to the 4, 5, 6 and 7 positions of 1-(4-benzoylpiperazin-1-yl)-2-(1H-indol-3-yl)ethane-1,2-dione, an inhibitor of the interaction between HIV gp120 and host cell CD4 receptors, on activity in an HIV entry assay was examined. Small substituents at C-4 generally resulted in increased potency whilst substitution at C-7 was readily tolerated and uniformly produced more potent HIV entry inhibitors. Substituents deployed at C-6 and, particularly, C-5 generally produced a modest to marked weakening of potency compared to the prototype. Small alkyl substituents at N-1 exerted minimal effect on activity whilst increasing the size of the alkyl moiety led to progressively reduced inhibitory properties. These studies establish a basic understanding of the indole element of the HIV attachment inhibitor pharmacophore.